Oncology Corporate Profile
Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need. The Company's most advanced program is talactoferrin, a first-in class oral Dendritic Cell Mediated Immunotherapy (DCMI). Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase I testing for cancer, and a topical gel form of talactoferrin for diabetic foot ulcers.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|talactoferrin||immunomodulatory protien||Non Small Cell Lung Cancer (NSCLC)||III|
|RGB-286638||multi-targeted protien kinase inhibitor||Various cancer types||I|
View additional information on product candidates here »